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Falls are the fifth-leading cause of death, globally, and they also come with social and 
economic burdens. In the individual level, falls can result in increased mortality, increased 
morbidity rate, reduced functioning such as physical activity, and reduced quality of life. 
Therefore, it is needed to be considered the falls as a single disease. Due to the clinical and social 
impact of falls, numerous studies were completed on the risk of falls on the elderly population 
and the diseased population related to motor dysfunction such as Parkinson's or stroke. However, 
there are still unmentioned diseases which have a higher risk of falls. Chronic Obstructive 
Pulmonary Disease (COPD) is a disease that has airflow limitation during breathing. COPD 
patients experience not only lack of oxygen supplementation but also systemic impairment such 
as cardiovascular problems, impaired muscle function, and impaired cognitive function. 
Therefore, we assessed the postural balance function and other related variables which were 
suggested in previous studies. Comorbidities, lung function, body composition, skeletal muscle 
strength, exercise capacity, balance function, physical activity status, and cognitive function 
were measured in the Healthy control group and the COPD group. Lung function showed lower 
values in the COPD group (FEV1, p<0.001), and comorbidity index was higher in the COPD 
group (Charlson Comorbidity Index, p<0.0001). Muscle strength was lower in the COPD group 
(inspiratory muscle strength, p=0.0007; maximal leg extension force, p=0.023) and the cognitive 
function was lower in the COPD group (p<0.0071). Also, the postural balance function measured 
by the center of pressure showed higher sway velocity in the COPD group (anterior-posterior 
direction, p<0.0081). However, no difference was found between the groups in Berg Balance 





was significantly associated with increased weight, years of COPD related symptoms, usage of 
oxygen, comorbidity index (congestive heart failure and diabetes), fat mass, and reduced 
cognitive function (p<0.05). The aforementioned factors in the COPD can be considered as risk 
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1.1 Significance of falls 
 Falls are the fifth-leading cause of death in the older population, and they also come with 
a burden not only to the individual patient but also can result in social and economic 
consequences [1]. The World Health Organization (WHO) reported that each year globally, 
approximately 646,000 individuals experience fatal falls that might require hospitalizations due 
to severe injuries such as fractures [2]. In the United States, approximately one in four older 
adults aged ≥ 65 reported falling each year, and 3 million U.S. residents visit emergency 
departments due to fall related episodes [3]. Furthermore, the death rate from falls increased in 
the U.S. by an average of 3.0% per year during 2007 to 2016 [3]. Falls also result in an increased 
burden of medical support [4]. For example, in the single patient aspect, falls can result in 
increased mortality and morbidity rates, as well as reduced functioning, which causes a direct 
reduction in physical activity [5] [6]. Moreover, these factors come along with a reduced quality 
of life [1]. Considering all the negative factors mentioned above, falls are a critical issue to think 
about equally to single disease. 
 
1.2 Factors of fall risk in general population 
 Due to the significance of falls, numerous studies were performed on the risk of falls. 
Approximately 400 different fall risk factors were reported [1] which shows that falls are not a 
simple issue. In healthy old populations, a number of studies reported that muscle weakness, 
balance deficit, number of medication, gait deficits, functional impairment, visual deficit, age, 
and cognitive impairment were intrinsic risk factors for falls [6] [4] [7] [8]. Also, environmental 






[4]. Postural stability is also known to be  affected by biomechanics, motor coordination, and 
sensory organization [9]. The findings of aforementioned research represent the fall risk factors 
of the healthy population. However, many diseases are associated with a significantly increased 
risk of falls which is not extensively researched. A number of studies show that an impaired 
balance function with increased fall risks was not only observed in motor-and neuro-related 
chronic diseases (e.g., Parkinson’s, stroke, etc.) but also other systemic diseases (e.g., COPD).  
 
1.3 Fall risk in the clinical population 
 Many researchers try to understand the underlying components of balance impairment — 
physiological, neuropsychological, and biomechanical mechanisms — and fall risk in the general 
and elderly populations [6] [4] [7] [8]. However, the dominant factors that are contributing to 
balance impairment might be different in every disease, and also it has not been clearly defined. 
Generally, these diseases have multiple negative effects on the risk of fall compared to a healthy 
population [10] [11].  In addition to the aforementioned studies, it is also not clearly known if 
COPD patients have the same risk factors for falls as a general elderly population or other 
diseases. Therefore, there is a critical need to identify the factors that contribute to impairment of 
balance function in COPD which increases risk of fall.    
 
1.4 What is COPD 
 According to the National Heart, Lung, and Blood Institute/World Health Organization 
(NHLBI/WHO) Global Initiative for Chronic Obstructive Lung Disease (GOLD), COPD is 
defined as “a disease state characterized by airflow limitation that is not fully reversible”[12]. 






cough, sputum production, or dyspnea. The confirmation of diagnosis for COPD is done by 
spirometry. Disease severity is classified by two component from spirometry such as Forced 
Expiratory Volume in the first one second (FEV1) and Forced Vital Capacity (FVC). With these 
values, FEV1/FVC ratio can be calculated that is also called the Tiffeneau-Pinelli index. To 
confirm the presence of airflow limitation that is not fully reversible, FEV1 < 80% of the 
predicted value and FEV1/FVC < 70% should be satisfied. Also, disease severity is classified 
with those factors [13]. In addition to GOLD staging, the COPD Assessment Test (CAT) and 
Modified British Medical Research Council (mMRC) questionnaire are used which are 
significantly related to physiological parameters of lung function [14] [15].  
  This airflow limitation of COPD is mainly caused by small airway disease and/or 
parenchymal destruction [16]. This structural change decreases the dimension of airway luminal 
area [17]. Chronic inflammation causes these structural changes, such as narrowing of the small 
airways and/or losing elasticity of recoil in alveolar [18]. Furthermore, this disease results in 
significant systemic disturbances along the whole body in organ function and biochemistry [19]. 
According to impairment in cardiovascular function, COPD patients have a 20% higher 
prevalence of heart failure [20] and vascular changes accompanied by arterial stiffness [21] and 
right ventricular failure [22]. Also, COPD can cause bone destruction by systemic inflammation 
[23] which results in a 60% higher prevalence of osteoporosis compared to people without 
COPD in the same age group. [24] [25]. In the muscular system, COPD subjects showed muscle 
atrophy, specifically reduced fat-free mass and cross-sectional area in type IIX fiber [26]. Also, 








1.5 What is known about balance impairment in COPD 
Interestingly, COPD patients showed a high incidence rate of falls [28] and balance 
impairment by traditional balance measurements. Crisan et al. reported that COPD subjects with 
an exacerbation showed worse outcomes than COPD subjects without an exacerbation using the 
Berg Balance Scale (BBS), Single-leg stance (SLS), and Timed-Up and Go test (TUG) [29]. 
Furthermore, impaired balance function measured by TUG was related to global functioning 
assessment score in COPD [30]. A balance impairment in COPD measured by Short Physical 
Performance Battery Score (SPPB), 4-meter gait speed, and sit-to-stand time were associated 
with physical inactivity [31]. However, these traditional balance measurement methods in COPD 
were focused on a comprehensive and systemic balance function, but not on the independent 
balance function. 
 
1.6 Limitations in previous studies  
Some of the current studies and methods mentioned above have limitations as well as 
lack of evidence. Measurements using a scale type scoring system might be affected by the 
tester’s bias. (e.g. inter-rater reliability) Also, these tests do not only have an insensitivity on 
mild balance impairment but also have a floor or ceiling effect [32]. In addition, these types of 
task-oriented tests mainly focused on the systemic function of the subject, but not specifically on 
the balance function [33, 34]. These limitations make it difficult for clinicians to detect balance 
impairment at diagnosis and to monitor the improvement during rehabilitation [35]. To manage 
this issue, a combination of multiple tests are recommended (e.g. ABC scale, FM-B, and PASS) 
[32]. Also, various methods were reported during the past few decades that enable measurement 






Especially, center-of-pressure measurement by force plate was intensively applied with clinical 
populations. These postural measurements were widely applied on neurological disorders (e.g. 
Parkinson’s disease, stroke) to quantify diagnostic balance function and to confirm improvement 
on balance function during rehabilitation [36]. These emerging technologies make clinically 
available to measure balance function and posture itself directly for other chronic diseases as 
well [37, 38]. Therefore, it is necessary to identify underlying causes of imbalance objectively by 
direct measurement of balance impairment.  
 
1.7 Objective of the present study 
The aims of the present study are 1) to investigate the presence of postural balance 
impairment in COPD patients determined by Center of Pressure (CoP) displacement 
measurement, and 2) to identify associating factors with postural balance impairment. To achieve 
our aims, we measured balance function by CoP trajectory and used calculations to convert it 
into quantifiable values. We hypothesized that a postural balance function is impaired in COPD 
due to dysfunction of skeletal muscle and cognition. Our research will contribute to identifying 
the high-risk fall patients prior to falls. Also, it will provide optimal and specific strategies for 













2. MATERIAL AND METHODS 
 
2.1 Subjects 
We recruited patients who were diagnosed with COPD by pulmonologists. 63 subjects 
were assessed for eligibility. 34 COPD and 22 Control subjects were included for data analysis 
who satisfies the inclusion criteria. Inclusion criteria for both groups were: age between 55 to 85 
years old, and be able to walk, sit, and stand up independently (Figure 1). COPD subjects were 
classified as moderate to severe airflow obstruction (grade ll-lV), according to the established 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines [39]. The control 
group consisted of 22 healthy participants matched with COPD for age, sex, and body-mass 
index (Table 1). Exclusion criteria were subjects who have: major neurological conditions that 
might affect postural balance (e.g., stroke history, Parkinson’s disease, etc.), the presence of an 
acute illness, a metabolically unstable chronic illness, or fever within three days prior to the 
study day. Recruitment of COPD patients took place through local pulmonologist referral, 
whereas healthy subjects were recruited via advertisements in the local community. Medical 
history and medication use were assessed by research staff as part of the screening process 
according to Health Insurance Portability and Accountability Act (HIPAA) Authorization. All 
COPD patients were in a clinically stable condition and not suffering from a respiratory tract 
infection or exacerbation of their disease at least 4 weeks prior to the study. Transcutaneous 
oxygen saturation was measured using pulse oximetry. Exclusion criteria were pre-existent 
untreated metabolic or renal disease, malignancy, recent surgery, and use of systemic 






bronchodilator medication, 16% inhalation corticosteroids, 44% were on long-term oxygen 
therapy and 22% were continuously on oxygen use. Written informed consent was obtained from 




Figure 1: Consort flow diagram of the study. 
 
2.2 Anthropometrics and body composition measurements 
All study day procedure was performed at the Human Clinical Research Facility of the 
Center for Translational Research in Aging and Longevity at Texas A&M University. The study 
procedures were identical in both groups and the study day lasted approximately 4 hours. Body 
weight and height were measured by a digital beam scale and stadiometer, respectively. 






(FFM) were obtained from all subjects while in a supine position, by dual-energy X-ray 
absorptiometry (DXA) (Hologic QDR 4500 / Version 12.7.3.1 (Bedford, MA)). Anthropometric 
and body composition were measured to obtain body mass index (BMI, kg/m^2), FFM index 
(FFMI), FM index (FMI), and appendicular skeletal muscle index (ASMI). Also, lower limb 
length was measured, from Trochanter major to Medial malleolus, by an embed software in 
Hologic QDR 4500 [40] to obtain muscle mass in lower limb [41].  
 
2.3 Lung function measurement 
Spirometry measurement was performed with a hand-held device (Microloop Peak flow 
Meter, CareFusion, San Diego, CA). With spirometry, lung function was measured by 
parameters, such as FEV1, FVC, and FEV1/FVC ratio. Forced expiratory volume in 1 second 
was assessed with the highest value from ≥ 3 technically acceptable maneuvers [42]. Subjects 
were asked to sit up straight and to wear a nose clip to seal their nose, and then asked to have 
three normal breaths (tidal breath). After three breaths, subjects were instructed to inhale as deep 
as they can and exhale as fast and as much as possible. The software expresses percentage of 
predicted value according to a representative population with the subject’s age and height 
information. Also, maximal expiratory pressure (MEP) and maximal inspiratory pressure (MIP) 
were assessed by determining the maximal value of at least 3 reliable attempts using a hand-held 
mouth pressure device (Micro Respiratory Pressure Meter). 
 
2.4 Muscle function and 6-meter gait speed (6MGS) measurement 
Skeletal muscle function and exercise tolerance were assessed in all subjects. To measure 






leg torque during one leg reciprocal extensions (at 60 degrees/sec) were measured. Also, a peak 
handgrip force that the subject was able to generate out of 3 reproducible repetitions, with 1 
minute of rest between each attempt, were used as a marker of maximum handgrip strength. Kin-
Com isokinetic dynamometry (Isokinetic International, Chattanooga, TN) and Vernier 
dynamometry (Vernier Software and Technology, Beaverton, OR) were used respectively. 6-
meter of usual and fast gait speed (6MGS) were measured to evaluate the tolerance of physical 
activity [43]. Time was measured over a distance of 6-meter after 1 trial of practice walk. Speed 
of usual and fast gait speed was calculated and expressed as meter/second. Subjects were 
allowed to use their walking aid and/or oxygen provided with a long tubing and movable 
cylinder [44].   
 
2.5 Balance function measurement using Berg Balance Scale (BBS) 
A performance-oriented and comprehensive balance function was evaluated by Berg 
Balance Scale in all subjects [45]. Berg Balance Scale (BBS) has been reported and used widely 
as a ‘gold standard’ for clinically assessing balance and postural control because of its 
documented reliability and validity [46-49]. BBS consists of 14 tasks that are common 
movements in everyday life that are scored by a 0 to 4 scale (items range from sit to stand and 
single leg stance) [45]. Research staff in our research facility had performed the test to maintain 
consistent inter and intra-rater reliability for the test as a whole (inter and intra- rater reliability 
reported as 0.98 and 0.99 respectively) [45]. The test was performed before the balance platform 









2.6 Postural balance function measurement using center of pressure (CoP) 
To obtain the measurable postural balance function, center of pressure (CoP) 
displacement data were collected. CoP displacement data were recorded by force plate (OR6-7-
8000, Advanced Mechanical Technology, Inc., MA) during given 30 seconds. Three trials of 
quiet standing (QS) were performed according to standard instruction [50]. To control supported 
area which is defined by area of feet and the distance between two foot (Appendix A and B) 
[51], the distance between both feet was instructed according to designated markers on the 
surface of plate [51]. CoP is a bivariate distribution defined by anterior-posterior (AP) and 
mediolateral (ML) coordinates [52]. Sway range (SR), sway velocity (SV), root-mean-square 
distance (RMS distance), and 95% of ellipse area (Area) [53] were calculated to characterize 
individual balance function in each group. We used 100 Hz sampling frequency of CoP which is 
suggested as a reliable measurement in the static balance [54]. Subjects were asked to stand 
barefoot on the firm surface of the force plate and arms at the sides. Standardized instruction was 
given to subject to maintain the balance as still as possible during the measurement. After the 
given instruction, 5 seconds were given to adjust the posture, and 30 seconds were given for the 
measurement.  A verbal cue sign for starting and ending were given by research staff with 
measuring time. Subjects were instructed to open their eyes and stare at the target which is 
located on a height of eye level and approximately 1.5 meters away.  Three trials were given and 
resting time was allowed in between each trial as subjects requested.  All the instruction to 








2.7 Cognitive function assessments  
To assess cognitive impairment and, we used a Trail Making Test (TMT) which is simple 
and sensitive to detect neurological impairment and processes [55]. TMT consists of two parts, 
TMT-A and TMT-B. TMT-A is a task with drawing line sequentially 25 encircled numbers (e.g., 
1 - 2 - 3 - 4, etc.). TMT-B is similar to TMT-A, but it is combined sequential numbers and 
alphabetical letters (e.g., 1 - A - 2 - B - 3 - C, etc.). Time for completion is measured during each 
part. The second test that we used to measure cognitive function was Stroop Color-Word Test 
[56]. Stroop test is a sensitive and reliable measurement method for neuropsychological response 
[55] [57]. According to the Stroop interference effect, an increased time is taken to name a color 
than to read out the name of a color [57]. There are possible theories to explain the Stroop effect, 
and the most common theories are regarding processing speed, selective attention function, and 
automaticity [58] [59]. Also, during the Stroop test, we can measure ability to selectively ignore 
the irrelevant stimuli and information [60]. We measured the time of completing Stroop reading 
tasks, and counted the number of errors. The Stroop test consists of three subtasks (l, ll, and lll). 
The materials for each subtask were shown on a white sheet of paper. The subjects were 
instructed to either read the name of the color or name of the ink color according to given 
subtasks. The first subtask shows color words in the random order that printed with black ink. 
The second subtask shows solid color patches among four colors. The third subtask shows color 
words printed in different ink color (e.g. the word “green” printed in “yellow” color) [61]. There 
was no time limit and completion time was measured for each task. Measured time was 
calculated for Stroop interference according to the equation below (1) [62]. 








On the study day, habitual physical activity level was measured by the Physical Activity 
Scale for the Elderly questionnaire (PASE). The PASE was designed to assess activities 
commonly engaged by older people whose age is 65 or older [63]. The COPD Assessment Test 
(CAT) was used to assess the status of disease [64]. For the assessment of associated 
comorbidities, we used the Charlson Comorbidity Index [65]. Charlson Comorbidity Index (CCI) 
is known as most common tool for risk adjusted assessment. CCI gives a score of 0 to 6 for each 
comorbidity according to the seriousness of each comorbidity (e.g. myocardial infarction, 
chronic heart failure, peripheral vascular disease, etc. as 1; hemiplegia, moderate to severe renal 
disease, diabetes with end organ damage, any tumor, etc. as 2; moderate or severe liver disease 
as 3; and metastatic solid tumor and AIDS as 6) [66]. Self-reported CCI was cross-checked with 
medical history of individual subjects if it is fully available. However, self-reporting CCI proved 
the predictive power in clinical parameters (e.g. 1 year mortality) [67].   
 
2.9 Data analysis  
The CoP displacements were measured by the force platform. Three quiet standings were 
given to subjects, and data were recorded during the 30 seconds of displacement (sampling 
frequency: 100 Hz) [68, 69]. From the quiet standing CoP displacement data, we calculated 1) 
sway range (SR), 2) mean sway velocity (SV), 3) root mean square distance (RMS distance), and 








Sway range (SR) was calculated as the distance of maximum value and minimum value on each 
coordinate respectively. Sway range (SR) in ML and AP were calculated with formula (2) and 
(3): 
    (2) 
    (3) 
Sway velocity (SV) consists of three sub-analyses: those were the anterior-posterior (AP), 
mediolateral (ML), and combined coordinates (AP and ML). Sway velocity (SV) was calculated 
with this formula (4): 
 (4) 
 
The root-mean-square distance was calculated to quantify the amount of variation of CoP sway. 
Root mean square (RMS distance X) was calculated with the formula below: 
 (5) 
 
Principal component analysis (PCA) was used to measure the body sway area approximated by 
an ellipse. Sway area (SA) was calculated to characterize individual patterns represented by the 
accumulation of a trajectory of CoP.  The PCA method quantifies the direction and the 
magnitude of the body sway [70]. 95% confidence ellipse was used for sway area calculation 
performed using Matlab code written by Marcos Duarte, available at the open-access public 








2.10 Statistical analysis 
All results are expressed as means ± standard errors (SE). Normality test was performed 
by D’Agostino-Pearson omnibus normality test or for small group numbers with Shapiro-Wilk 
normality test. Unpaired Student’s t-test was used to compare two groups at a time. If the 
normality test failed, unpaired Mann-Whitney test was performed instead. To test the association 
between postural balance function and all demographic variables, body composition related 
variables, comorbidity, cognitive function, and muscle strength. Pearson’s correlation coefficient 
was used. The statistical packages within GraphPad Prism (GraphPad Software, La Jolla, CA, 
Version 8) and Matlab (The MathWorks, Inc., Natick, MA) were used for data analysis. The 





















According to subject recruitment between 2017 and 2019, 66 subjects were included in 
the study: 22 control and 34 COPD subjects.  Age, gender, and BMI were matched in both 
groups for analysis. In the Control group, the age range of 55 to 84 years and 50% were male. In 
the COPD group, the age range was 55 to 81 years and 41% were male (NS). There was no 
difference between the groups in age, gender, body weight, height, BMI, or physical activity 
level (NS). COPD subjects showed higher CCI score (0.31 vs 2.08, p < 0.001) (Table 1). 
 
Table 1: General and clinical characteristics of the Control and COPD groups. 





Age (years) 70.44 (1.72) 68.97 (1.36) 0.505 
Gender (Male/Female) 11/11 14/20 0.588 
Body Weight (kg) 82.36 (2.26) 83.32 (3.47) 0.838 
Height (m) 1.67 (0.01) 1.65 (0.01) 0.326 
Body mass index (kg/m
2
) 29.50 (0.79) 30.53 (1.20) 0.528 
Charlson comorbidity index (score) 0.31 (0.12) 2.08 (0.25)** <0.0001 
PASE (score) 122.0 (18.22) 106.4 (12.46) 0.507 
Values are mean ± SE. Statistics are by unpaired t-test or Mann-Whitney test when normal distribution test failed. 











As we expected according to inclusion criteria on the diagnosis of COPD, the pulmonary 
related factors showed a lower lung function in the COPD group, and also average FEV1 
predicted percentage showed 44.18% (p < 0.0001). Oxygen saturation was lower in the COPD 
group than the Control group (97.32% vs. 95.00%, p = 0.014).  20 subjects out of 34 were 
currently having oxygen therapy (including subjects who are using oxygen as needed, all day, 
and night only) (Table 2). 
 
Table 2: Pulmonary functions of the Control and COPD group. 





FEV1 (% of predicted) 96.91 (2.96) 44.18 (3.13)** <0.0001 
FVC (% of predicted) 87.68 (2.79) 57.91 (2.38)** <0.0001 
FEV1/FVC (ratio) 82.45 (1.27) 56.79 (2.70)** <0.0001 
Years of COPD related symptom (yr.) - 10.82 (1.11) - 
Hospitalizations previous 12m. for exacerbation (No.)  0.26 (0.10) - 
Exacerbations in the past year (No.) - 0.73 (0.24) - 
GOLD Stage - 2.87 (0.13) - 
Dyspnea Scale - 2.09 (0.18) - 
CAT (score) - 21.00 (1.26) - 
O2 use (yes/no) 0/22 20/14 - 
Oxygen saturation (%) 97.32 (0.33) 95.00 (0.70)* 0.014 
Values are mean ± SE. Statistics are by unpaired t-test or Mann-Whitney test when normal distribution test failed. 
Categorical data were analyzed with Chi-square test. GOLD: Global Initiative for Chronic Obstructive Lung Disease. 
FEV1: Forced Expiratory Volume in one second. FVC: Forced Vital Capacity. CAT:  COPD Assessment Test. No.: 









In body composition, there was no difference between fat, lean, and muscle related 
variables. However, skeletal muscle function showed lower values in inspiratory muscle strength 
(p = 0.0007) and maximal leg extension force (p = 0.023). Leg extension force per kg fat-free 

























Table 3: Body composition and muscle functions of the Control and the COPD group.  
 Control, n=22  
(SE) 




Lean mass (kg) 49.00 (2.27) 48.51 (1.94) 0.871 
Lean mass extremities (kg) 20.77 (0.91) 19.41 (0.90) 0.318 
Fat mass (kg) 28.56 (1.65) 32.28 (1.91) 0.178 
Fat mass trunk (kg) 15.22 (1.06) 17.03 (1.12) 0.275 
Fat mass index (kg/m
2
) 10.36 (0.68) 11.95 (0.78) 0.163 
Fat-free mass (kg) 53.64 (1.89) 50.72 (2.19) 0.355 




19.09 (0.44) 18.46 (0.63) 0.478 
Appendicular skeletal muscle mass (kg)
 
20.77 (0.91) 19.41 (0.90) 0.318 




7.365 (0.22) 7.053 (0.25) 0.400 
Android fat (%)
4 
37.54 (1.78) 38.53 (1.83) 0.715 
Gynoid fat (%)
4 
35.10 (2.00) 37.91 (1.31) 0.226 
Fat % android/gynoid (ratio) 1.101 (0.05) 1.015 (0.04) 0.205 
Lower limb lean mass (kg) 15.67 (0.57) 14.53 (0.65) 0.223 
Muscle function 
Inspiratory muscle strength (cmH2O) 83.50 (4.27) 60.97 (4.22)** 0.0007 
Expiratory muscle strength (cmH2O) 100.90 (8.02) 82.71 (5.90) 0.068 
Maximal handgrip strength (N) 235.80 (16.58) 203.40 (10.47) 0.087 
Handgrip strength per kg fat-free mass (N/kg) 4.34 (0.21) 4.091 (0.17) 0.362 
Maximal leg extension force (N) 257.70 (13.31) 210.50 (13.86)* 0.023 
Maximal leg extension force per kg fat-free mass (N/kg) 4.82 (0.20) 4.15 (0.19)* 0.026 
Maximal leg extension force per kg fat-free mass lower 
limb (N/kg) 
33.49 (1.36) 28.63 (1.18)* 0.010 
Values are mean ± SE. Statistics are by unpaired t-test. 
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Android fat and 
gynoid fat correspond to central and peripheral fat distribution, respectively. COPD: chronic obstructive pulmonary 







The traditional balance measurement, Berg Balance Scale, did not show a difference 
between the groups (NS). However, usual and fast gait speed measurements showed lower 




Figure 2: Berg Balance Scale (A), max score is 56; Gait speed for 6-meter distance walking (B: 
















The neurological test results showed that the COPD group needed more time to complete 
the given task in TMT (Figure 3 - A, p < 0.0071). The Stroop test did not show a statistical 
difference, but the COPD group tended to be significantly longer in the interference time (Figure 
3 - B, p < 0.061). 
 
 
















In the CoP displacement, the COPD group had a significantly greater velocity than the 
Control group in AP and ML combined direction (Figure 4 - A, p < 0.023) and AP direction 
(Figure 4 - B, p < 0.0081). However, Sway area and Sway range did not show a difference 
between the groups (Figure 4 - D, E, and F). 
 
Figure 4: Postural balance function between the groups (A: Sway velocity of AP and ML 
combined direction; B: Velocity of AP direction; C: Velocity of ML direction, D: Sway area, 











In the Control and the COPD group, Pearson’s correlation analysis was performed to 
identify association with postural balance function and other variables. Weight, age, systolic 
blood pressure, years of COPD related symptoms, and presence of oxygen therapy were 
positively correlated to AP sway velocity in the COPD group. Of the Charlson Comorbidity 
Index, the presence of diabetes was highly correlated with sway velocity (r = 0.6635, p < 0.0001) 
(Table 4 and figure 5). Also, in the variable of body composition, greater fat related variables 
(e.g., fat mass and fat percentage) were related to worse postural balance function. Interestingly, 
longer task time in the Stroop test was correlated to worse postural balance function (r = 0.5927, 
p < 0.0002).    
 
Table 4: Correlation analysis between the AP sway velocity and other variables.  
Correlation Control COPD 






Weight 0.1071 0.6266 0.3725 0.0300 
Age 0.5977 0.0026 0.5089 0.0021 
Systolic BP 0.5555 0.0059 0.3945 0.0209 
COPD related symp. (yr.)  0.3787 0.0298 





CCI 0.0059 0.3138 0.6635 <0.0001 
Congestive heart failure  0.5241 0.0015 
Dia. w/o organ damage -0.0050 0.9819 0.6361 <0.0001 
Dia. w/ organ damage  0.519 0.0017 
Body comp. Fat mass 0.1195 0.5869 0.3783 0.0274 
Fat mass extremities 0.0289 0.8958 0.4418 0.0089 
Fat percentage  -0.0077 0.9719 0.3563 0.0386 
Cognitive Stroop interference 0.7630 <0.0001 0.5927 0.0002 
Stroop part 3 0.6635 0.0006 0.4841 0.0037 








Figure 5: Correlation between AP velocity and variables in the COPD group. 
 
In the Figure 6, cutoff analyses were done with the variable which was significantly 
correlated with AP sway velocity. This stratification figure, the presence of congestive heart 
failure (p = 0.0015), presence of any diabetes (p < 0.0001), COPD related symptoms more than 
10 years (p = 0.037), usage of any oxygen therapy (p = 0.021), Charlson Comorbidity Index 2 or 
higher (p = 0.009), age over 75 years old (p = 0.0143), and over 130 seconds in Stroop subtask C 















4. DISCUSSION AND SUMMARY 
 
Regarding impaired balance function in COPD, there is a need for identifying associated 
factors that could provide reliable detection for a potential risk of falls. In the present study, we 
used a postural balance function measurement which was impaired in the COPD group compared 
to the healthy group with the same age, gender, and BMI. We identified that velocity of CoP in 




Despite no statistical difference found between the two groups according to age, gender, 
and BMI matching, the Control and COPD group showed a male-to-female ratio of 1.0 and 0.7, 
respectively. Expected factors that were possibly affected by the gender ratio are skeletal muscle 
function and body composition [72] [73]. According to our data, no gender difference on 
postural sway was found between the groups (p=0.8799). This finding is in contrast to other 
research [74].    
 
4.2 Muscle functions and balance impairment in COPD 
Our results indicated that balance function and skeletal muscle function is impaired in 
COPD patients. However, we could not find a relationship between skeletal muscle function and 
balance function, especially lower limb strength, and maximum handgrip strength. One possible 
explanation regarding the results of relationship is that protocol of muscle function measurement 






the knee with a speed of 60 degrees/sec. This knee extension for maximal voluntary contraction 
represents recruitment of slow-twitch muscle fibers (type l) than fast-twitch fibers (type II) [75]. 
However, a knee is not only contributing factor in posture, but also combining ankle and hip 
strategy were reported previously [76]. Therefore, the muscle strength measurement that we used 
might not be able to explain the relationship between the muscle function and postural balance 
function.  
 
4.3 Neurological function and balance impairment in COPD 
We found that neurological function was lowered in COPD and also showed strong 
association between the greater postural sway velocity and cognitive dysfunction in COPD. 
Although, the COPD group showed lower cognitive function, both groups showed a similar 
degree of correlation between CoP AP velocity and Stroop time (Healthy vs. COPD, p < 0.0001 
vs. p = 0.0002). Since the underlying mechanism of the Stroop test is not yet fully established, 
we can only assume possible explanations for the correlation between the postural impairment 
and a longer time in the Stroop test. One possible explanation is that COPD patients have a 
reduced attention due to exposure to chronic hypoxemia. The impaired attention might be 
contributed to a longer reaction time against a body sway because of latency of cognition. The 
other possible explanation is that impaired coordinating function in the posture is affected by 
dysfunction in sensory reception and integration that is caused by hypoxia related neuronal 
damage [77].  Furthermore, in a recent study, a structural change in the brain was reported 








4.4 Comorbidity, diabetes and balance impairment in COPD 
Higher presence of diabetes in CCI and diabetes related risk factors were found in COPD. 
Also, strong correlations were found between greater sway velocity and CCI and diabetes related 
risk factors (fat mass, fat percentage, presence of CHF, and systolic BP). Therefore, we can 
assume that these factors might have contributed to the impairment in posture. Possible 
explanation is impairment in neurological pathway in diabetic patients, for example, diabetic 
neuropathy. Juster-Switlyk [79] reported that 50% of diabetic patient experience polyneuropathy 
during their lifetime which is supporting balance impairment in diabetic patients. Also, it is 
widely known that congestive heart failure (CHF) is common in diabetes patients. CHF was 
prevalent in over 11% of diabetic patients, and age, duration of disease, presence of 
hypertension, insulin usage were associated incidence of CHF [80]. These references are 
supporting our data showing that the presence of diabetes, the presence of congestive heart 
failure, and increased blood pressure are associated with postural balance impairment. Not only 
the comorbidity, but also the body composition showed a greater fat mass in the COPD group 
which is aligning to diabetic risk factor. Weight gain accompanied by an increased fat mass is 
commonly reported in diabetic patients [81]. However, we have a limited number of subject who 
has glucose concentration data which did not show meaningful correlation (n = 17, p = 0.3927). 
Analysis of HbA1c or serum leptin level will give us better understanding regarding correlation 










4.5 Possible mechanisms of balance impairment in COPD 
As we found in the sway velocity results, the greater postural velocity of the COPD group 
might be explained by: 1) a latency in sensory input of postural disturbance relating to three 
major system (vestibular, visual, somatosensory feedback)[83, 84] and/or 2) a higher number of 
posture adjustment [85] [86] with fine control of muscle which is relating to neuromuscular 
system. According to previous studies, Roig [87] reviewed articles to identify contributing 
factors on balance impairment and falls. Muscle weakness, gait deficit, nutritional depletion, 
impaired activities of daily living, and the number of medication were mentioned as risk factors 
for falls. However, the underlying mechanism for increased postural sway among the COPD 
subjects is still unknown. Possible mechanisms were found in other chronic diseases such as the 
cerebellar disorder [88] or somatosensory deficit [89]. For example, polyneuropathy with nerve 
conduction abnormalities showed a slower reaction time, worse static balance, and an increased 
number of falls [90] [91] [92]. Appenzeller et al suggested that long-lasting disturbance by 
COPD disease might lead to the breakdown of peripheral myelin [93]. Furthermore, the damage 
of myelin could be contributed to a reduced nerve conduction velocity [94]. This reduced nerve 
activity might contribute to a delayed response against perturbations. Also, polyneuropathy has 
shown to be related to a reduced single-leg stance, gait speed, lower limb muscle function, and 
an increased fall incidence. As we found a high association between sway velocity and oxygen 
usage and a presence of diabetes and fat mass and cognitive function in COPD, we suggest a 










Our research used the magnitude based postural sway as a balance function of the 
subjects that were calculated by the displacement of the center of pressure. However, a center of 
mass (CoM) is another key factor regarding human posture and balance [9, 95]. This motion of 
CoM is also closely related to the CoP [96, 97]. In general, the CoM can be detected by either a 
reaction board or a segmentation method [98]. Although we could not find a postural CoP 
difference between genders, the difference between genders was reported on relative height of 
the CoM [99].  Therefore, considering CoM with CoP together, this can provide more sensitive 
results [100, 101]. Furthermore, regarding estimating stability, CoM value can be calculated 
using the base of support that can be measured by distance of both feet and length of feet [101] 
and body weight [102]. To overcome these limitations of single method, CoP measurement by 
force plate, approaching with multiple methods would be needed.       
 
4.7 Future research 
Further research is necessary because approaching with multiple methods is needed to 
increase the sensitivity of detecting balance impairment instead of only using a CoP 
measurement. For example a motion capture system or accelerometer measurement can be 
applied to clearly characterize balance function in COPD. In this study, we found that there were 
various sub-characteristics of COPD in terms of comorbidities and/or related symptoms, oxygen 
therapy usage status, and etc. Therefore, it is necessary to increase the number of subjects to 
categorize/characterize subjects and analyze the purified data (e.g. COPD with Obstructive Sleep 
Apnea, COPD with diabetes, with or without oxygen therapy, and etc.) to better understand the 






function assessment, it is also needed to collect a blood sample and analyze, such as serum leptin 
level, tryptophan and/or serotonin (5-HT) metabolism.  
 
4.8 Summary 
In summary, we have found general risk factors for postural balance impairment in 
COPD such as age, but we also identified COPD specific risk factors such as the use of oxygen, 
years of COPD related symptoms, comorbidities, and diabetes related factors. Future research is 
needed to clarify the given risk factor for postural balance impairment to prevent falls or improve 
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